Linked Life Data

15102095

Source:http://linkedlifedata.com/resource/pubmed/id/15102095

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2004-4-22
pubmed:abstractText
A preliminary clinical experience suggested tazarotene, a new acetylenic retinoid, as an effective alternative topical treatment of basal cell carcinomas (BCC). The mechanisms of action of this synthetic retinoid, however, have not been yet clarified. In this work we assessed the in vivo effects of daily application of tazarotene for 24 wk, on 30 small superficial and nodular BCC, and the in vitro effects of tazarotene on immortalized basal and squamous tumor epidermal cells. Cellular proliferation, apoptosis and changes in expression of retinol and retinoic acid receptors (RAR), p53, bcl-2, and bax were studied by immunohistochemistry, western blotting and PCR. Overall, 76.7% of treated tumors showed >50% regression. Complete healing was observed in 46.7% of all treated BCC, without recurrences at 2-y observation. Regression was associated with reduced proliferation and increased apoptosis, demonstrated by Ki-67- and TdT-mediated dUTP-biotin nick-end labelling-positive nuclear staining, and with enhanced RAR-beta and bax expression, with RAR-alpha and -gamma expression unchanged. In vitro, tazarotene induced a concentration-dependent increase of RAR-beta and bax associated with a greater rate of apoptosis and growth inhibition in basaloid tumor cells compared with squamous tumor cells. Our studies provide convincing evidence that tazarotene induces BCC regression possibly by synergistic RAR-beta-dependent anti-proliferative and pro-apoptotic pathways.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
0022-202X
pubmed:author
pubmed:issnType
Print
pubmed:volume
122
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1037-41
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:15102095-Adult, pubmed-meshheading:15102095-Aged, pubmed-meshheading:15102095-Aged, 80 and over, pubmed-meshheading:15102095-Apoptosis, pubmed-meshheading:15102095-Carcinoma, Basal Cell, pubmed-meshheading:15102095-Carcinoma, Squamous Cell, pubmed-meshheading:15102095-Cell Division, pubmed-meshheading:15102095-Cell Line, Tumor, pubmed-meshheading:15102095-Dermatologic Agents, pubmed-meshheading:15102095-Drug Administration Schedule, pubmed-meshheading:15102095-Humans, pubmed-meshheading:15102095-Middle Aged, pubmed-meshheading:15102095-Nicotinic Acids, pubmed-meshheading:15102095-Proto-Oncogene Proteins, pubmed-meshheading:15102095-Proto-Oncogene Proteins c-bcl-2, pubmed-meshheading:15102095-Receptors, Retinoic Acid, pubmed-meshheading:15102095-Skin Neoplasms, pubmed-meshheading:15102095-Treatment Outcome, pubmed-meshheading:15102095-bcl-2-Associated X Protein
pubmed:year
2004
pubmed:articleTitle
Evidence of increased apoptosis and reduced proliferation in basal cell carcinomas treated with tazarotene.
pubmed:affiliation
Department of Biopathology and Image Diagnostics, Anatomic Pathology Institute, University of Rome, Italy. orlandi@uniroma2.it
pubmed:publicationType
Journal Article, Clinical Trial, Research Support, Non-U.S. Gov't